United States Sex Reassignment Hormone Therapy Market to Grow with a CAGR of 4.29% through 2029

Rise in research and development is expected to drive the United States Sex Reassignment Hormone Therapy Market growth in the forecast period, 2025-2029.

According to TechSci Research report, “United States Sex Reassignment Hormone Therapy Market – By Region, Competition, Forecast and Opportunities, 2029F”, the United States Sex Reassignment Hormone Therapy Market stood at USD 1.21 billion in 2023 and is anticipated to grow with a CAGR of 4.29% through 2029. The field of transgender healthcare in the United States has undergone significant progress, notably in the realm of Sex Reassignment Hormone Therapy (HRT). In recent years, there has been a notable increase in societal awareness and acceptance of transgender individuals and their specific healthcare needs. This cultural shift has been instrumental in driving the demand for gender-affirming treatments, with hormone therapy emerging as a critical component of the transition process. The expansion of health insurance coverage for transgender-related healthcare has further fueled the growth of the HRT market, making hormone therapy more financially accessible to transgender individuals by reducing out-of-pocket expenses.

The United States has witnessed a rise in medical expertise in transgender healthcare, with a growing number of healthcare providers specializing in this area. As more professionals receive specialized training, the quality of care has improved, and the availability of healthcare providers offering hormone therapy has expanded, thus lowering barriers to access for transgender individuals. Continuous research and development in hormone therapy have led to the development of safer and more effective treatment options, instilling confidence in patients and driving increased demand for hormone therapy. These advancements not only enhance the safety of treatment but also enable more tailored hormone regimens, ultimately improving the overall quality of care provided to transgender individuals.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "United States Sex Reassignment Hormone Therapy Market”

The United States Sex Reassignment Hormone Therapy Market is segmented into Gender Transition, Type, Distribution Channel, Regional Distribution, And Company.

Based on the Gender Transition, Male-To-Female emerged as the fastest growing segment in the United States Sex Reassignment Hormone Therapy Market in 2023. Research and data indicate that there is a higher incidence of MTF (Male-to-Female) transitions compared to FTM (Female-to-Male) transitions. This greater prevalence results in a larger population seeking MTF hormone therapy, leading to an increased demand for these services. MTF individuals, who are often assigned male at birth, typically require estrogen and anti-androgen medications to develop secondary female sex characteristics, such as breast growth and softer skin. For many MTF individuals, hormone therapy is considered medically necessary to alleviate gender dysphoria, which is the psychological distress stemming from the mismatch between one's gender identity and assigned sex at birth. Hormone therapy plays a vital role in addressing this distress, underscoring the importance of these treatments.

Based on the Type, Estrogen emerged as the dominant segment in the United States Sex Reassignment Hormone Therapy Market in 2023. Estrogen therapy often results in more noticeable and psychologically comforting changes, including breast growth, redistribution of body fat, decreased body hair, and softer skin. These physical transformations can significantly alleviate gender dysphoria, the emotional distress stemming from the misalignment between one's gender identity and assigned sex at birth, thereby increasing the demand for estrogen therapy. MTF (Male-to-Female) transitions are more prevalent than FTM (Female-to-Male) transitions, leading to a greater need for estrogen. Individuals who were assigned male at birth and desire to transition to a female gender typically require estrogen therapy to develop secondary female sex characteristics like breast growth, softer skin, and fat redistribution. For many transgender individuals undergoing MTF transition, estrogen therapy is considered medically essential to effectively address gender dysphoria. This medical necessity serves as a key driver behind the substantial demand for these treatments.

Mid-West emerged as the fastest growing region in the United States Sex Reassignment Hormone Therapy Market in 2023. The Midwest region has made notable progress in enhancing healthcare access for transgender individuals. This advancement encompasses an increasing presence of specialized healthcare facilities and providers offering transgender healthcare services, facilitating easier access to hormone therapy for individuals within the region. The Midwest has been actively engaged in raising awareness and promoting education on transgender healthcare. Local organizations and advocacy groups have been instrumental in fostering public understanding and diminishing stigma surrounding transgender healthcare, consequently driving up the demand for hormone therapy services.

Major companies operating in United States Sex Reassignment Hormone Therapy Market are:

• Viatris Inc.
• AbbVie Inc.
• ASCEND Therapeutics US, LLC.
• Pfizer Inc.
• Eli Lilly and Company
• Novartis AG
• Endo International plc.

Download Free Sample Report

Customers can also request for 10% free customization on this report

“The United States market for Sex Reassignment Hormone Therapy (HRT) is poised for substantial growth in the foreseeable future. Increasing societal awareness and acceptance of gender diversity, coupled with a supportive legal and policy framework, will continue to drive individuals towards seeking gender-affirming care, including hormone therapy. The expanding coverage of gender-affirming treatments by health insurance plans will enhance the accessibility of HRT to a wider demographic. Telehealth services are expected to play a crucial role, offering convenient and confidential access to specialized care. Additionally, ongoing research and development endeavors will contribute to enhancing the quality and safety of hormone therapy, ultimately leading to improved patient outcomes”, said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“United States Sex Reassignment Hormone Therapy Market By Gender Transition (Male-To-Female, Female-To-Male), By Type (Puberty Blockers, Estrogen, Testosterone), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) Region and Competition, Opportunity, and Forecast, 2019-2029F”, has evaluated the future growth potential of United States Sex Reassignment Hormone Therapy Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in United States Sex Reassignment Hormone Therapy Market.

Contact

Techsci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +13322586602

Email: [email protected]               

Website: www.techsciresearch.com